impairment header

Have a case? 

Impaired Risk Specialists
since 1959
 

 

Underwriting 101 - Melanoma
 

Dear (Contact First Name),
 

Hello, and welcome to our first edition of Impairment Profile for 2012. We hope to bring you more technical information on impairments we see every day. This may not be for you and that is fine.  However, I get questions daily on different diseases, so I thought why not tell you some of what I know! 

Melanoma

 

Melanoma, a cancer of melanocytes, which are cells that produce skin

pigmentation, is the most serious type of skin cancer encountered in the underwriting process. The National Cancer Institute estimated that for 2011 70,230 people in the United States would be diagnosed with melanoma and that 8,790 would die from this cancer. Annual spending on melanoma treatment was estimated to be about $1.9 billion in 2010. The incidence rate of melanoma has been steadily rising.

 

Risk Factors

Some risk factors for the development of melanoma include ultraviolet light exposure, including sunlight, atypical (also known as dysplastic) moles, multiple benign moles, fair complexion, a family or personal history of melanoma, and conditions and medications that suppress the immune system.

 

After Diagnoses

Once melanoma has been diagnosed, a number of factors help predict

prognosis, including thickness (thicker tumors are more serious); the mitotic rate, which reflects how rapidly the cancer cells are dividing (a higher mitotic rate has a worse prognosis); whether ulceration is present, which means that the top layer of skin over the melanoma is missing (ulceration is associated with a worse outcome); and whether the melanoma has spread to lymph nodes or to other areas of the body. These factors are used to help determine the melanoma's stage, which is closely tied to expected survival. For example, according to the American Cancer Society, Stage IA melanoma, which is less than 1.0 mm in thickness, is not ulcerated, has a low mitotic rate, and has not spread to lymph nodes or distant organs, has a ten year survival rate of around 95%. However, if the melanoma is Stage IV, meaning that it has spread to other organs or distant parts of the body, the ten year survival is only about 10% to 15%. Sometimes the doctor may biopsy the sentinel lymph node, which is considered to be the first lymph node that would contain metastatic disease, and if negative then spread to other lymph nodes is considered to be unlikely.

Case Studies -  

 

Applicant 1 had Stage IA melanoma removed four years ago. There is no family history of melanomaand annual checkups with the dermatologist have been normal.

Underwriting Offer: Standard Plus

 

Applicant 2 had a 3mm melanoma with ulceration removed over 5 years ago. Follow-up visits with the dermatologist have been favorable. Due to the thickness of the cancer and the ulceration, the prognosis here is worse.

Underwriting Offer: Table 2 + $10 flat extra

 

Applicant 3 was treated two years ago for melanoma metastatic to 3 lymph nodes. A parent and sibling died from melanoma. The applicant has not seen a doctor for 18 months.

Underwriting Offer: Decline

I hope you have found this useful.  We will send this out monthly.  If you have an impairment you would like for me to highlight, simply drop me a note!
  
Sincerely,

 


Patty Longmire

In-House Underwriter

plongmire@tba.com

865.588.9555 x13

800.624.4502 x13
Tennessee Brokerage Agency